Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches (original) (raw)
An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
luisa Arna
CNS & Neurological Disorders - Drug Targets, 2011
View PDFchevron_right
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease
Mojgan Aghazadeh Tabrizi, Nicola Simola
Journal of The Neurological Sciences, 2006
View PDFchevron_right
Past, present and future of A 2A adenosine receptor antagonists in the therapy of Parkinson's disease
marie armentero
Pharmacology & Therapeutics, 2011
View PDFchevron_right
Targeting adenosine A 2A receptors in Parkinson's disease
Kjell Fuxe
Trends in Neurosciences, 2006
View PDFchevron_right
New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
Jadwiga Wardas
Life Sciences, 2005
View PDFchevron_right
Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease
Roberto Rimondini
Parkinsonism & Related Disorders, 2001
View PDFchevron_right
Adenosine A2Areceptor antagonist treatment of Parkinson’s disease
Francesco Bibbiani
Neurology, 2003
View PDFchevron_right
Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease
Jadwiga Wardas
Neurotoxicity Research, 2001
View PDFchevron_right
Adenosine A2A-Receptor Antagonism and Pathophysiology of Parkinson’s Disease and Drug-Induced Movement Disorders
Jaime Kulisevsky
European Neurology, 2012
View PDFchevron_right
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications
Jadwiga Wardas
Progress in Neurobiology, 2007
View PDFchevron_right
A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease
Miquel Casas
Clinical Neuropharmacology, 2002
View PDFchevron_right
Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys
Ronald Pearce
Annals of Neurology, 1998
View PDFchevron_right
Adenosine A 2A receptors, dopamine D 2 receptors and their interactions in Parkinson's disease
Kjell Fuxe
Movement Disorders, 2007
View PDFchevron_right
Discovery of nonxanthine adenosine A 2A receptor antagonists for the treatment of Parkinson's disease
Colin T Dourish
Neurology, 2003
View PDFchevron_right
A2A adenosine receptor overexpression and functionality, as well as TNF- levels, correlate with motor symptoms in Parkinson's disease
Pier Borea
The FASEB Journal, 2010
View PDFchevron_right
Adenosine A 2A Receptor Antagonists: New 8-Substituted 9-Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease
Catia Lambertucci
ChemMedChem, 2009
View PDFchevron_right
Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats
Rafael Lujan
Disease Models & Mechanisms, 2014
View PDFchevron_right
Parkinson’s disease: will therapy move beyond dopaminergic medication?
László Vecsei
Clinical Investigation, 2011
View PDFchevron_right
Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis
Ping Lin
Neurological Research, 2014
View PDFchevron_right
Adenosine A 2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter Lewitt
Annals of Neurology, 2008
View PDFchevron_right
Untangling dopamine-adenosine receptor assembly in experimental parkinsonism
Francisco Ciruela
Disease Models & Mechanisms, 2014
View PDFchevron_right
Targeting Adenosine Receptors in Neurological Diseases
Ayman Ali
Cellular Reprogramming, 2021
View PDFchevron_right
Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity
Soha Essawy
Archives of Medical Science
View PDFchevron_right
Enhanced ATP release and CD73‐mediated adenosine formation sustain adenosine A 2A receptor over‐activation in a rat model of Parkinson's disease
Paula Agostinho
British Journal of Pharmacology, 2019
View PDFchevron_right
Adenosine A2A receptors in Parkinson’s disease treatment
Andrzej Wojtczak
Purinergic Signalling, 2008
View PDFchevron_right
Enhanced ATP release and CD73‐mediated adenosine formation sustain adenosine A 2A receptor over‐activation in a rat model of Parkinson's disease
Rodrigo Cunha
British Journal of Pharmacology, 2019
View PDFchevron_right
Adenosine–Dopamine Interactions Revealed in Knockout Mice
Karima Chergui
Journal of Molecular Neuroscience, 2005
View PDFchevron_right
Adenosine A 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
Paula Canas, Rodrigo Cunha
Annals of Neurology, 2008
View PDFchevron_right
Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys
Ronald Pearce
Experimental Neurology, 2000
View PDFchevron_right
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
Imtiaz Ahmed
Neurology, 2011
View PDFchevron_right